Similarly, the proportion of CD38+ TAMs was not altered after the addition of anti-CSF-1R in both tumor types in comparison with the original IT, and the number of Egr2+ TAMs only marginally decreased after the addition of anti-CSF-1R into treated mice with TC-1/A9 tumors (Figure 7C). This evidence concerns the gene CD38 and neoplasm.